Activities                          (5,000,000)              - 
                                       ------------   ------------ 
 
Cash Flows From Financing 
Activities: 
Proceeds from common stock option 
 exercises                                        -         31,267 
Merger, net                             (3,831,357) 
Net proceeds from registered direct 
 offerings                               13,803,684     13,798,183 
                                       ------------   ------------ 
   Net Cash Provided By Financing 
    Activities                            9,972,327     13,829,450 
                                       ------------   ------------ 
 
Net Change in Cash and Cash 
 Equivalents                           (23,229,048)   (15,230,762) 
Cash and Cash Equivalents -- 
 Beginning of Year                       26,480,928     41,711,690 
                                       ------------   ------------ 
Cash and Cash Equivalents -- End of 
 Year                                 $   3,251,880  $  26,480,928 
                                       ============   ============ 
 
Supplemental Disclosures of Cash 
Flow Information and Non-cash 
Activities: 
 
IPR&D Milestones included in License 
 Payable                              $  28,400,000  $           - 
Prepaid Manufacturing transferred to 
 Inventory                            $   6,134,895  $           - 
 
Reflects a 1-for-25 reverse stock split effective November 25, 2024. 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339718.html

SOURCE Citius Pharmaceuticals, Inc.

(END) Dow Jones Newswires

December 27, 2024 17:00 ET (22:00 GMT)